Insider · CIK 0001730229
William Grossman
Files at DAWN (Day One Biopharmaceuticals, Inc.), ENGN (enGene Therapeutics Inc.). First filing Sep 24, 2026, latest Sep 24, 2026.
William Grossman files SEC Form 4 as officer and director at ENGN (enGene Therapeutics Inc.), and also at DAWN (Day One Biopharmaceuticals, Inc.). Since Sep 24, 2026, William Grossman has reported 1 open-market buy worth $10k and 0 open-market sells worth $0, the latest filed on Sep 24, 2026.
A track record needs three past buys with six months of prices behind them; William Grossman has 0, so none is measured yet.
The newest scored trade: bought $10k of ENGN on Sep 22, 2026, filed Sep 24, 2026, scored 23 (weak). In the last 12 months: 1 buy worth $10k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ENGN: enGene Therapeutics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | ENGN enGene Therapeutics Inc. | POpen-market purchase Common Shares | +5,102 | $1.97 | $10k | 5,102 | 19 d ago |
| Jun 16, 2026 | ENGN enGene Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +31,000 | $0.00 | $0 | 31,000 | Jun 17, 2026 |
| Jun 16, 2026 | ENGN enGene Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jun 17, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -66,660 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -32,335 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -22,500 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Restricted Stock Unit (RSU)derivative | -15,000 | - | - | 0 | Apr 23, 2026 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -66,660 | $0.00 | $0 | 0 | Nov 7, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Stock Option (right to buy Common Stock)derivative | +66,660 | $0.00 | $0 | 66,660 | Nov 7, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -32,335 | $0.00 | $0 | 0 | Nov 7, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Stock Option (right to buy Common Stock)derivative | +32,335 | $0.00 | $0 | 32,335 | Nov 7, 2025 |
| Jul 8, 2025 | ENGN enGene Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jul 10, 2025 |
| Jun 2, 2025 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Stock Option (right to buy Common Stock)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 4, 2025 |
| Jun 2, 2025 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Restricted Stock Unit (RSU)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 4, 2025 |
Questions about William Grossman
Answered from the filings on this page, as of the latest one.
Is William Grossman buying or selling?
In the last 12 months William Grossman reported 1 open-market buy worth $10k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $10k of ENGN on Sep 22, 2026. Grants, option exercises and tax withholding are not counted.
How did William Grossman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and William Grossman has 0.
Where does William Grossman file Form 4?
William Grossman has filed Form 4 at ENGN (enGene Therapeutics Inc.) as Interim Chief Medical Officer; DAWN (Day One Biopharmaceuticals, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.